Catalyst
Slingshot members are tracking this event:
Merck (MRK) Announces Phase 3 Data Evaluating Letermovir in Clinically Significant Cytomegalovirus (CMV) Infection in CMV-Seropositive Adults Who Have Undergone an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 19, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Data Readout, Letermovir, Clinically Significant, Cytomegalovirus, Cmv-seropositive, Allogeneic Hematopoietic Stem Cell Transplant
